

Anti-Human CD279 (PD1) Antibody

| | |
|---------------------------|------------------|
| Catalog Number: | 101401, 101402 |
| Size: | 100 ug, 500 ug |
| Target Name: | CD279, PD1, PD-1 |
| Regulatory Status: | RUO |

PRODUCT DETAILS

| | |
|-------------------------------|--|
| Clone: | 279AM1 |
| Application: | Flow Cytometry |
| Reactivity: | Human |
| Format: | Purified |
| Isotype: | Mouse IgG1 |
| Antibody Type: | Monoclonal |
| Formulation: | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide |
| Protein Concentration: | 0.5 mg/mL |
| Storage&Handling: | The antibody solution should be stored between 2°C and 8°C |
| Recommended Usage: | For flow cytometric staining, it is recommended to use less than 0.2 ug of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. |
| Isotype Control: | 301401 |

BACKGROUND INFORMATION

CD279, also known as Programmed Cell Death Protein 1 (PD-1), is a crucial immune checkpoint receptor that regulates T cell activation and prevents autoimmunity. This transmembrane protein plays a pivotal role in maintaining immune homeostasis by delivering inhibitory signals that dampen excessive immune responses.


PD-1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It contains an extracellular immunoglobulin variable (IgV)-like domain, a transmembrane region, and an intracellular tail with two tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). When engaged, these motifs recruit phosphatases that inhibit T-cell receptor signaling, effectively suppressing T-cell activation, proliferation, and cytokine production.

PD-1 interacts with two primary ligands: PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). PD-L1 is widely expressed on various cell types, including tumor cells, antigen-presenting cells, and non-hematopoietic tissues, while PD-L2 expression is more restricted to antigen-presenting cells. These ligand-receptor interactions serve as critical brakes on immune responses. In cancer, tumor cells exploit the PD-1/PD-L1 pathway to evade immune surveillance. By upregulating PD-L1 expression, tumors effectively "turn off" infiltrating T-cells, preventing effective anti-tumor immunity. This mechanism contributes to tumor progression and immune escape

across multiple cancer types.

The discovery of PD-1's role in cancer has revolutionized oncology through immune checkpoint inhibitors. Monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab) block this inhibitory pathway, reinvigorating anti-tumor T-cell responses. These therapies have demonstrated remarkable success in treating melanoma, non-small cell lung cancer, renal cell carcinoma, and numerous other malignancies, fundamentally transforming cancer treatment paradigms and offering durable responses in previously untreatable cancers.

PRODUCT DATA



Human peripheral blood lymphocytes stimulated with Anti-Human CD3/CD28 for three days were stained with purified anti-Human CD279 (PD-1) clone 279AM1 (color-filled histogram), followed by PE Anti-Mouse IgG.

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.